3 January 2018 - VistaGen Therapeutics announced today that the U.S. FDA has granted fast track designation to AV-101 for development as a potential adjunctive treatment for major depressive disorder. 

VistaGen's lead CNS product candidate, AV-101, is in Phase 2 development, initially as a new generation oral antidepressant drug candidate for major depressive disorder (MDD). AV-101's mechanism of action is fundamentally different from all FDA-approved anti-depressants and atypical antipsychotics used adjunctively to treat MDD, with potential to drive a paradigm shift towards a new generation of safer and faster-acting anti-depressants.

Read VistaGen Therapeutics press release